Primary Sclerosing Cholangitis (PSC)
Primary Sclerosing Cholangitis (PSC) is a rare liver disease that causes inflammation and scarring of the bile ducts, leading to liver damage and complications.
We are studying the safety and effectiveness of low-dose interleukin-2 therapy for patients with conditions like Pemphigus vulgaris and Mucous Membrane Pemphigoid. This trial aims to see how well this treatment works compared to a placebo.
Health conditions and diseases that the clinical trial is designed to study and treat.
Primary Sclerosing Cholangitis (PSC) is a rare liver disease that causes inflammation and scarring of the bile ducts, leading to liver damage and complications.
Mucous Membrane Pemphigoid is a rare autoimmune disorder that causes blistering and scarring of mucous membranes, particularly in the mouth and eyes.
Polymyositis and Dermatomyositis are rare inflammatory diseases that cause muscle weakness and skin rashes, affecting the body's ability to move and function.
Pemphigus Vulgaris and Pemphigus Foliaceus are rare autoimmune diseases that cause painful blisters and sores on the skin and mucous membranes.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.